Trial Profile
A Prospective Observational Study to Evaluate Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Simponi (Golimumab)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms GO-COX
- Sponsors Merck Sharp & Dohme
- 05 Jun 2021 Primary endpoint (Change of BASFI (Bath Ankylosing Spodylitis Functionality Index)) has been met, according to results /presented at the 22nd Annual Congress of the European League Against Rheumatism.
- 05 Jun 2021 Status changed from active, no longer recruiting to completed, according to Results presented at the 22nd Annual Congress of the European League Against Rheumatism..
- 05 Jun 2021 Results assessing clinical changes measured by BASFI, BASMI, BASDAI, ASDAS-CRP and radiological changes in AS patients with coxitis (BASRI-hip, hip MRI [STIR- and T1-weighted sequences], hip US) after 12 and 24 months of treatment , presented at the 22nd Annual Congress of the European League Against Rheumatism.